Runway Growth’s recent expansion into life sciences gains quick traction

The debt provider launched the strategy and hired Rob Lake in April and has seen attractive opportunities since as the sector continues to see elevated activity.

While launching a new strategy in the midst of a market downturn may not seem like a wise choice, for Runway Growth Capital it looks like perfect timing.

In April, the venture debt lender announced the expansion of its strategy to include life science companies, It also hired industry veteran Rob Lake as a managing director and head of the new investment area.

Three months later, the firm has opened a new hub in San Diego, has added a deal to its portfolio and is seeing demand start to stick.

“The level of interest I’m getting from my contacts and colleagues is that there is definitely a need for another player like Runway to come into the space,” Lake said.

Lake joined the firm with 16 years of experience in life science venture debt. He was most recently at Bridge Bank as the founder and head of the life sciences group. Since joining Runway, he hit the ground running and closed the strategy’s first deal in July.

Runway
Rob Lake is a managing director and the head of life sciences at Runway Growth.

The firm supplied a $30 million senior-secured loan to Intact Vascular, a medical device start-up. The Wayne, Pennsylvania-based company also raised a Series D round in May from New Enterprise Associates, Quaker Partners and Vensana Capital, among others.

The team is underway on its second deal. Lake said they are interested in companies across the many life sciences sectors and are looking to lend between $10 million and $75 million per transaction.

“We are looking for companies that are in a high-growth phase, whether it is revenue growth or cashflow growth,” Lake said. “It’s early in their launch, but they have strong clinical data. We would really like to see strong enterprise value in our deals.”

He added that the only area they will avoid are companies looking for the capital to reach an inflection point, such as an expected FDA approval or potential clinical trial.

The firm plans to do a handful of deals in 2020, which Lake said should set them up for a solid first year.

Runway is tapping into the life sciences market in the midst of a potentially record-breaking year. The sector saw $14.8 billion invested across 781 deals in H1. This shows a 24 percent increase over the $11.2 billion invested across 729 deals last year, according to PitchBook and the National Venture Capital Association (NVCA).

The market looks likely to match or surpass 2019’s total of $23 billion.

The increase in activity has also driven up the average and median deal size in the sector. The median deal size increased from $4.2 million in 2019 to $4.6 million in H1 2020. Average deal size was up 26 percent from $15.5 million in 2019 to $21 million in 2020.

Lake said that he wasn’t sure if and when the life sciences strategy at Runway would rival or match its tech portfolio. But he said that the supply and demand in the market would allow it.

“There is always a way to continue to improve healthcare. There is always going to be a need,” Lake said. “I think this is going to be an interesting space for a good number of years. At least that’s the hope.”